Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1986 Aug;30(2):211–214. doi: 10.1128/aac.30.2.211

Imipenem-cilastatin as initial therapy for febrile cancer patients.

G P Bodey, M E Alvarez, P G Jones, K V Rolston, L Steelhammer, V Fainstein
PMCID: PMC180520  PMID: 3532942

Abstract

Imipenem-cilastatin was used to treat 79 febrile episodes in 71 cancer patients, most of whom had neutropenia. The overall response rate was 67%, and 76% of the 45 documented infections responded. The response rates for septicemias and pneumonias were 79 and 62%, respectively. Only 1 of the 17 infections caused by gram-negative bacilli failed to respond to this therapy. The most common side effects were skin rash, nausea, and diarrhea. Eight superinfections were detected during therapy.

Full text

PDF
214

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barza M. Imipenem: first of a new class of beta-lactam antibiotics. Ann Intern Med. 1985 Oct;103(4):552–560. doi: 10.7326/0003-4819-103-4-552. [DOI] [PubMed] [Google Scholar]
  2. Bodey G. P. Antibiotics in patients with neutropenia. Arch Intern Med. 1984 Sep;144(9):1845–1851. [PubMed] [Google Scholar]
  3. Bodey G. P., Grose W. E., Keating M. J. Use of trimethoprim-sulfamethoxazole for treatment of infections in patients with cancer. Rev Infect Dis. 1982 Mar-Apr;4(2):579–585. doi: 10.1093/clinids/4.2.579. [DOI] [PubMed] [Google Scholar]
  4. Bodey G. P., Ketchel S. J., Rodriguez V. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med. 1979 Oct;67(4):608–616. doi: 10.1016/0002-9343(79)90242-0. [DOI] [PubMed] [Google Scholar]
  5. Bodey G. P., Rodriguez V., Luce J. K. Carbenicillin therapy of gram-negative bacilli infections. Am J Med Sci. 1969 Jun;257(6):408–414. doi: 10.1097/00000441-196906000-00007. [DOI] [PubMed] [Google Scholar]
  6. Bulger R. J. In vitro effectiveness of kanamycin and kanamycin/cephalothin against Klebsiella. Comparison with other antibiotics. Ann Intern Med. 1967 Sep;67(3):523–532. doi: 10.7326/0003-4819-67-3-523. [DOI] [PubMed] [Google Scholar]
  7. Calandra G. B., Hesney M., Grad C. A multiclinic randomized study of the comparative efficacy, safety and tolerance of imipenem/cilastatin and moxalactam. Eur J Clin Microbiol. 1984 Oct;3(5):478–487. doi: 10.1007/BF02017380. [DOI] [PubMed] [Google Scholar]
  8. Fainstein V., Bodey G. P., Bolivar R., Elting L., McCredie K. B., Keating M. J. Moxalactam plus ticarcillin or tobramycin for treatment of febrile episodes in neutropenic cancer patients. Arch Intern Med. 1984 Sep;144(9):1766–1770. [PubMed] [Google Scholar]
  9. Fainstein V., Bodey G. P., Elting L., Bolivar R., Keating M. J., McCredie K. B., Valdivieso M. A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients. J Antimicrob Chemother. 1983 Jul;12 (Suppl A):101–110. doi: 10.1093/jac/12.suppl_a.101. [DOI] [PubMed] [Google Scholar]
  10. Garcia I., Bodey G. P., Fainstein V., Ho D. H., LeBlanc B. In vitro activity of WIN 49375 compared with those of other antibiotics in isolates from cancer patients. Antimicrob Agents Chemother. 1984 Sep;26(3):421–423. doi: 10.1128/aac.26.3.421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gribble M. J., Chow A. W., Naiman S. C., Smith J. A., Bowie W. R., Sacks S. L., Grossman L., Buskard N., Growe G. H., Plenderleith L. H. Prospective randomized trial of piperacillin monotherapy versus carboxypenicillin-aminoglycoside combination regimens in the empirical treatment of serious bacterial infections. Antimicrob Agents Chemother. 1983 Sep;24(3):388–393. doi: 10.1128/aac.24.3.388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Klastersky J., Cappel R., Daneau D. Therapy with carbenicillin and gentamicin for patients with cancer and severe infections caused by gram-negative rods. Cancer. 1973 Feb;31(2):331–336. doi: 10.1002/1097-0142(197302)31:2<331::aid-cncr2820310210>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  13. Klastersky J., Henri A., Hensgens C., Daneau D. Gram-negative infections in cancer. Study of empiric therapy comparing carbenicillin-cephalothin with and without gentamicin. JAMA. 1974 Jan 7;227(1):45–48. doi: 10.1001/jama.227.1.45. [DOI] [PubMed] [Google Scholar]
  14. Lawson R. D., Gentry L. O., Bodey G. P., Keating M. J., Smith T. L. A randomized study of tobramycin plus ticarcillin, tobramycin plus cephalothin and ticarcillin, or tobramycin plus mezlocillin in the treatment of infection in neutropenic patients with malignancies. Am J Med Sci. 1984 Jan-Feb;287(1):16–23. doi: 10.1097/00000441-198401000-00004. [DOI] [PubMed] [Google Scholar]
  15. Lumish R. M., Norden C. W. Therapy of neutropenic rats infected with Pseudomonas aeruginosa. J Infect Dis. 1976 May;133(5):538–547. doi: 10.1093/infdis/133.5.538. [DOI] [PubMed] [Google Scholar]
  16. McLaughlin F. J., Matthews W. J., Jr, Strieder D. J., Sullivan B., Taneja A., Murphy P., Goldmann D. A. Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo. J Infect Dis. 1983 Mar;147(3):559–567. doi: 10.1093/infdis/147.3.559. [DOI] [PubMed] [Google Scholar]
  17. Middleman E. L., Watanabe A., Kaizer H., Bodey G. P. Antibiotic combinations for infections in neutropenic patients. Evaluaton of carbenicillin plus either cephalothin or kanamycin. Cancer. 1972 Aug;30(2):573–579. doi: 10.1002/1097-0142(197208)30:2<573::aid-cncr2820300238>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  18. Piccart M., Klastersky J., Meunier F., Lagast H., Van Laethem Y., Weerts D. Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia. Antimicrob Agents Chemother. 1984 Dec;26(6):870–875. doi: 10.1128/aac.26.6.870. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Stuart R. K., Braine H. G., Lietman P. S., Saral R., Fuller D. J. Carbenicillin-trimethoprim/sulfamethoxazole versus carbenicillin-gentamicin as empiric therapy of infection in granulocytopenic patients. A prospective, randomized, double-blind study. Am J Med. 1980 Jun;68(6):876–885. doi: 10.1016/0002-9343(80)90217-x. [DOI] [PubMed] [Google Scholar]
  20. Tally F. P., Jacobus N. V., Gorbach S. L. In vitro activity of thienamycin. Antimicrob Agents Chemother. 1978 Sep;14(3):436–438. doi: 10.1128/aac.14.3.436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Winston D. J., Barnes R. C., Ho W. G., Young L. S., Champlin R. E., Gale R. P. Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients. Am J Med. 1984 Sep;77(3):442–450. doi: 10.1016/0002-9343(84)90100-1. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES